Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252896 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 | |
| SCHEMBL2249244 | 0.88 | LMNA (0.42) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 | |
| SCHEMBL2552704 | 0.88 | LMNA (0.42) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 | |
| SCHEMBL8271406 | 0.87 | GRM1 (0.48) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 | |
| SCHEMBL2248312 | 0.87 | GRM1 (0.48) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 | |
| SCHEMBL2244620 | 0.87 | GRM1 (0.48) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 | |
| SCHEMBL2247206 | 0.87 | GRM1 (0.48) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 | |
| SCHEMBL2550594 | 0.85 | PANK3 (0.46) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 | |
| SCHEMBL2249362 | 0.85 | PANK3 (0.46) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 | |
| SCHEMBL2550452 | 0.85 | PANK3 (0.46) | KDM4EALDH1A1NPSR1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | claimed |
| EP-1771421-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | SERONO LAB (CH) | 2009-04-29 | — | — | EP | claimed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | claimed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | disclosed |
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| EP-1771421-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | SERONO LAB (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | KDM4E 2539/4885ALDH1A1 354/4885NPSR1 495/4885 |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | HCAR2, HNMT, HPGD | KDM4E 2486/4885ALDH1A1 313/4885NPSR1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.